Why do we fail with penicillin in the treatment of group A streptococcus infections?

Shlomo Sela*, Asher Barzilai

*Corresponding author for this work

Research output: Contribution to journalEditorial

Abstract

Acute pharyngotonsillitis caused by β-haemolytic group A streptococcus (GAS) is a common childhood disease. Phenoxymethyl penicillin remains the drug of choice, as no resistance has been reported so far. Nevertheless, the failure of penicillin to eradicate streptococci from the throat occurs in up to 35% of patients with pharyngotonsillitis, and might present clinical concern. Various explanations have been proposed over the years to account for this perplexing phenomenon. Among these are coexistence of oropharyngeal β-lactamase-producing bacteria that degrade penicillin, growth interference by aerobic and anaerobic commensals, penicillin tolerance, reinfection, and poor antibiotic compliance. Although GAS has been considered an extracellular pathogen, recent studies have demonstrated that strains of this bacterium can internalize epithelial cells both in vitro and in vivo. The intracellular niche may protect the bacterium from penicillin that does not gain high intracellular concentration. In support of this hypothesis, GAS strains were shown to survive 4-7 days inside cultured epithelial cells. In addition, it was found that GAS strains isolated from patients with eradication failure harbour the internalization-associated gene, prtF1/sfbI, in higher prevalence than do strains recovered from patients with successful eradication. Thus, internalization and intracellular survival represent a novel explanation for penicillin eradication failure.

Original languageEnglish
Pages (from-to)303-307
Number of pages5
JournalAnnals of Medicine
Volume31
Issue number5
DOIs
StatePublished - Oct 1999
Externally publishedYes

Fingerprint

Dive into the research topics of 'Why do we fail with penicillin in the treatment of group A streptococcus infections?'. Together they form a unique fingerprint.

Cite this